Relapse prevention in schizophrenia: attitudes of neurologists-psychiatrists.
The overall high relapse rates observed in schizophrenia are attributed to several causes. One important factor influencing satisfactory prevention of relapse is the lack of consistent treatment strategies among medical doctors, especially neurologists-psychiatrists. Nearly one-third of the members of the Hellenic Society of Neurology and Psychiatry were asked to fill in anonymously a structured questionnaire on their treatment attitudes and prescribing tactics regarding schizophrenic patients both after the first schizophrenic episode and after multiple episodes. The majority of Greek neurologists-psychiatrists seem to adopt prescribing habits that approximate the current international standards for prevention of schizophrenic relapse. Their attitudes regarding the treatment and prevention of relapse for the first schizophrenic episode and first relapse are determined from multiple factors. These are: the expected relapse rates after the first episode, the expected prevalence of extrapyramidal side effects following a long-term neuroleptic treatment, the patient's expected treatment compliance after the first episode, the doctor's experience with treating schizophrenics, and lastly the knowledge of current literature on the topic. These results point to the need for continuing education, especially of the younger mental health professionals and those working in the private sector, addressing the issue of the actual risk of developing side effects from the treatment. In due course, benefits could result for everyday psychiatric practice and the patients' compliance with treatment.
Bergiannaki
J D
JD
University Mental Health Research Institute, Eginition Hospital, Vas. Sophias Ave. 72-74, GR115 28 Athens, Greece. bergian@compulink.gr
Hatzimanolis
J
J
Liappas
J
J
Sakkas
P N
PN
Stefanis
C N
CN
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001291:Attitude of Health Personnel; D005260:Female; D006115:Greece; D006220:Haloperidol / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008605:Mental Health Services / Q000592:standards*; D009462:Neurology / Q000592:standards / Q000706:statistics & numerical data*; D010349:Patient Compliance; D010353:Patient Education as Topic; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011570:Psychiatry / Q000592:standards / Q000706:statistics & numerical data*; D012559:Schizophrenia / Q000188:drug therapy*; D055502:Secondary Prevention; D011795:Surveys and Questionnaires; D013997:Time Factors
D014150:Antipsychotic Agents; D006220:Haloperidol